Clinical Trial Detail

NCT ID NCT02848651
Title A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST]
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Genentech, Inc.
Indications

lung non-small cell carcinoma

Therapies

Atezolizumab

Age Groups: adult senior

Additional content available in CKB BOOST